Occam Global Recruits CFO for eGenesis
August 12, 2026 – New York City-based executive search firm Occam Global has placed Glenn Vraniak as CFO of eGenesis, a biotechnology company developing human-compatible engineered organs for transplantation. “eGenesis is entering a pivotal stage in our evolution as we prepare to advance our programs through clinical development and lay the foundation for future commercialization,” said Mike Curtis, CEO of eGenesis. “Glenn brings deep expertise and proven leadership across finance, capital formation, and business development and we are thrilled to have him join the team to help drive the next phase of growth for the company.”
Mr. Vraniak brings more than two decades of executive leadership experience across biotechnology, medical technology and specialty pharmaceuticals, with a track record of leading capital raising initiatives, IPOs, strategic transactions and company-building initiatives. Most recently, he served as CFO of Inversago Pharma, where he helped lead the company’s growth strategy, financing activities and eventual acquisition by Novo Nordisk in a transaction valued at approximately $1.1 billion. Prior to that, Mr. Vraniak served as CFO of Evaxion Biotech, Valeo Detection Systems and electroCore. He also served on the board of directors of Apollomics Inc, where he chaired the audit committee.
Throughout his career, Mr. Vraniak has helped raise hundreds of millions of dollars in private and public capital, led IPO processes and supported strategic transactions across both public and private companies. Most recently, at Inversago, he completed a $70 million Series C financing, prepared the company for a potential IPO and played a key role in negotiating its acquisition by Novo Nordisk.
“eGenesis has built one of the most innovative platforms in biotechnology and is addressing one of the largest unmet needs in medicine,” said Mr. Vraniak. “The opportunity to revolutionize the treatment of organ failure and potentially save countless lives is incredibly compelling. I look forward to working alongside this talented team as we advance our clinical programs, strengthen our operational capabilities and position the company for long-term success.”
Headquartered in Cambridge, MA, eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The company’s proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses.
Founded in 2012 by William Holodnak, Occam Global is an international executive recruiting and leadership advisory firm specializing in building management teams for companies in the life sciences, AI, robotics, defense, technology, and venture capital sectors. The firm’s success is rooted in cultivating and valuing relationships, establishing trust with entrepreneurs, executives, and investors. The firm employs a disciplined and comprehensive method for the sourcing, selection, and integration of executive leaders, involving in-depth research and rigorous due diligence. In addition, Occam Global provides sophisticated advice on organizational structure and development at the C-suite and board levels.
Related: Occam Global Fills Senior Post for Variant Bio
Mr. Holodnak established his reputation by starting, building, and running an international search firm servicing leading companies and entrepreneurial organizations in the asset management, financial services, global health and biotechnology sectors throughout Asia, North America, and Europe. Prior to founding Occam, Mr. Holodnak created J. Robert Scott, a multinational executive search firm under the umbrella of Fidelity Investments. He specializes in recruiting C-level executives and board of director searches for the financial services and healthcare sectors, with clients including MIT, Ameriprise, the Bill & Melinda Gates Foundation, AstraZeneca, Venrock, New Enterprise Associates, and SingHealth.
Occam Global Recruits Former CSO of Novo Nordisk to Advisory Board of Cradle
Occam Global has placed Marcus Schindler as a member of the advisory board at Cradle, the enterprise-grade AI platform for protein engineering. He will help accelerate the platform’s scientific impact and drive broader adoption of AI-powered protein engineering across the life sciences industry. “Marcus is renowned for modernizing drug discovery at some of the world’s largest pharmaceutical companies,” said Stef van Grieken, co-founder and CEO of Cradle. “He has been transformative in building thriving cultures that turn technology into a genuine competitive advantage, disrupt drug discovery to deliver better outcomes and adopt AI solutions at larger scale. We’re excited to work closely with Marcus and draw on his deep experience driving R&D innovation to apply AI in practical, meaningful ways across biologics discovery and development.”
John Holodnak is Occam Global’s president. He specializes in healthcare executive recruiting and technology executive recruiting, calling on nearly a decade of experience in C-level executive search and his extensive experience in the financial services sector. Mr. Holodnak previously worked as an equity analyst at Crédit Agricole, a fixed-income analyst at Western Asset Management, and a currency trader on Wall Street.
Aura Biosciences Search
Occam Global also recently recruited Natalie Holles as CEO of NASDAQ-traded Aura Biosciences in Boston, MA. “We are delighted to welcome Natalie as CEO at this important moment for Aura,” said David Johnson, chairman of the board of directors of Aura Biosciences. “Natalie brings significant experience across late-stage development, operations, and rare disease commercialization, making her exceptionally well-suited to lead Aura as we near completion of enrollment in our Phase 3 CoMpass trial and prepare for potential commercialization. On behalf of the board, I would like to thank Elisabet for her leadership and vision in founding Aura and advancing the company to this critical point.”
Ms. Holles has more than 25 years of executive leadership experience spanning corporate strategy, business development, operations and commercialization across multiple therapeutic areas. Prior to joining Aura, Ms. Holles served as CEO of Third Harmonic Bio from August 2021 through December 2025.
Related: Occam Global Places Leader of Gene Therapy Company Ensoma
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
